The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
A phase II clinical trial has launched to study Lutathera® in adolescents with gastroenterpancreatic neuroendocrine tumors (GEP-NET), pheochromocyomas and paragangliomas (PPGLs).
The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD
A phase II clinical trial has opened to investigate the safety and effectiveness of the drug belzutifan for pancreatic neuroendocrine tumors (pNETs) and pheochromocytoma/paraganglioma (PPGL).
Etay Ziv, MD, PhD, an interventional radiologist at Memorial Sloan Kettering Cancer Center in New York, leads a translational research study, funded by NETRF through the American Association for Cancer Research, that aims to understand the process of how pancreatic NETs progress from low grade to higher, more aggressive grade tumors.
Doctors at University of California San Francisco (UCSF) are conducting the first-of-its-kind e-NET study to learn about symptoms and quality of life for patients with neuroendocrine cancer. This is your chance to become a citizen scientist and help the researchers learn more about NETs.